Paul Stewart graduated from Edinburgh Medical School in 1982 and trained in Edinburgh, Dallas and Birmingham with accreditation in Endocrinology/Diabetes Mellitus and General Internal Medicine. From 1992-2002 he held a MRC Senior Clinical Fellowship in Birmingham and since then has held an honorary Consultant contract with the University Hospitals Birmingham Foundation NHS Trust. In 1995 he was awarded a personal Chair in Medicine and Fellowship of the Royal College of Physicians of London and in 1999 was elected as a Fellow of the Academy of Medical Sciences. He is currently Dean of Medicine at the University of Birmingham.
Paul supervises an active Endocrinology research group funded currently by programme grant support from The Wellcome Trust (but also MRC, ERC, NIH and industry) that focuses on corticosteroids, specifically cortisol metabolism via 11ß-hydroxysteroid dehydrogenases. His work has led to new discoveries in hypertension, obesity, inflammation, osteoporosis and ageing and is truly translational as selective 11ß-HSD1 inhibitors are in phase II development for patients with Metabolic Syndrome.
He has a major commitment to Clinical Medicine both within the NHS Trust and at National and International level. Clinical expertise includes the management of Pituitary and Adrenal disorders and Endocrine hypertension. Nationally, he serves or has served on Society for Endocrinology committees, Wellcome Trust Molecular and Physiological Sciences Strategy and Capital Investment committees, and is currently Chair of the MRC Careers Group with a seat on MRC Strategy Board. He is a Trustee/Council member of the BHF. Internationally, he has played a leadership role in the US Endocrine Society and is Secretary Treasurer for the International Society of Endocrinology.
He has over 250 original peer reviewed publications and has delivered over 150 plenary/symposium lectures to specialist societies including the RCP Linacre, Goulstonian and Simms lectures, the RCP Graham Bull prize, the Society for Endocrinology Medal Lecture, the Clinical Endocrinology Trust Medal Lecture, Sir George Pickering Medal, and the Clinical Investigator Award Plenary Lecture at The Endocrine Society.
Lawson AJ, Walker EA, Lavery GG, Bujalska IJ, Hughes B, Arlt W, Stewart PM, Ride JP (2011), Cortisone-reductase deficiency associated with heterozygous mutations in 11ß-hydroxysteroid dehydrogenase type 1. Proceedings of the National Academy of Sciences of the United States of America (PNAS), (in print).
Semjonous NM, Sherlock M, Jeyasuria P, Parker KL, Walker EA, Stewart PM, Lavery GG (2011), Hexose-6-phosphate dehydrogenase contributes to skeletal muscle homeostatis independent of 11ß-hydroxysteroid dehydrogenase type 1. Endocrinology, 152(1): 93-102.
Tiganescu A, Walker EA, Hardy R, Mayes AE, Stewart PM (2011), Localization, age- and site-dependent expression and regulation of 11ß-hydroxysteriod dehydrogenase type 1 in skin. Journal of Investigative Dermatology, 2011; 131(1): 30-36.
Edwards NC, Ferro CJ, Kirkwood H, Chue CD, Young AA, Stewart PM, Steeds RP, Townend JN (2010), Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. American Journal of Cardiology, 106(10): 1505-1511.
Sinclair AJ, Walker EA, Burdon MA, van Beek AP, Kema IP, Hughes BA, Murray PI, Nightingale PG, Stewart PM, Rauz S, Tomlinson JW (2010), Cerebrospinal fluid corticosteroid levels and cortisol metabolism in patients with idiopathic intracranial hypertension: a link between 11ß-HSD1 and intracranial pressure regulation? Journal of Clinical Endocrinology and Metabolism, 95(12): 5348-5356.
Sinclair AJ, Burdon MA, Nightingale PG, Ball AK, Good P, Matthews TD, Jacks A, Lawden M, Clarke CE, Stewart PM, Walker EA, Tomlinson JW, Rauz S (2010), Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. British Medical Journal 341: c2701.
Sherlock M, Reulen RC, Alonso AA, Ayuk J, Clayton RN, Sheppard MC, Hawkins MM, Bates AS, Stewart PM (2009), ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. Journal of Clinical Endocrinology Metabolism, 94(11): 4216-4223.
Vassiliadi DA, Barber TM, Hughes BA, McCarthy MI, Wass JA, Franks S, Nightingale P, Tomlinson JW, Arlt W, Stewart PM (2009), Increased 5-reductase activity and adrenocortical drive in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 94(9): 3558-3566.